Related Experiment Video

Updated: Jun 23, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

Biological effects of hexitol and altritol-modified siRNAs targeting B-Raf

Michael Fisher1, Mikhail Abramov, Arthur Van Aerschot

  • 1Department of Pharmacology, School of Medicine, University of North Carolina, Chapel Hill, NC 27599, USA.

European Journal of Pharmacology
|April 21, 2009
PubMed

Insights

Certain hexitol modifications enhance the effectiveness and duration of small interfering RNAs (siRNAs) targeting the B-Raf oncogene in melanoma. Altritol modifications showed less improvement compared to unmodified siRNAs.

Area of Science:

  • Oligonucleotide chemistry
  • Cancer biology
  • Melanoma therapeutics

Background:

  • Small interfering RNAs (siRNAs) are crucial for gene silencing.
  • The B-Raf oncogene drives melanoma growth and survival.
  • Chemical modifications can enhance siRNA stability and efficacy.

Purpose of the Study:

  • To investigate the impact of altritol and hexitol modifications on B-Raf targeting siRNAs.
  • To assess the efficacy and duration of action of modified B-Raf siRNAs in melanoma.

Main Methods:

  • Synthesis of altritol and hexitol modified oligonucleotides.
  • In vitro assays including apoptosis, DNA synthesis, and colony formation.
  • Measurement of B-Raf protein and message levels.

Main Results:

  • Hexitol-modified B-Raf siRNAs demonstrated improved effectiveness and prolonged action.
  • Altritol-modified siRNAs were comparable or less effective than unmodified siRNAs.
  • Modifications were well-tolerated at various positions on the siRNA strands.

Conclusions:

  • Specific hexitol modifications can significantly enhance B-Raf siRNA performance in melanoma.
  • Increased nuclease stability may contribute to the enhanced efficacy of hexitol-modified siRNAs.
  • These findings support the development of chemically modified siRNAs for cancer therapy.

More Related Videos

Bioluminescence Resonance Energy Transfer (BRET)-Based Assay for Measuring Interactions of CRAF with 14-3-3 Proteins in Live Cells06:44

Bioluminescence Resonance Energy Transfer (BRET)-Based Assay for Measuring Interactions of CRAF with 14-3-3 Proteins in Live Cells

Published on: March 1, 2024

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...